Results 101 to 110 of about 10,318 (317)

Use of GLP-1 receptor agonists and risks of suicide attempts or self-harm in patients with type 2 diabetes: a multicountry self-control case series study

BMJ Mental Health
Background Inconclusive findings regarding the association between suicidal ideation/suicide attempt and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been recently revealed in a small number of studies.Methods This was a multinational self ...
Ian Chi Kei Wong, Eric Yuk Fai Wan, Huang-Tz Ou, Esther Wai Yin Chan, Vincent Ka Chun Yan, Zi-Yang Peng, Vincent Kai Chung Wong   +6 more
doaj   +1 more source

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study [PDF]

, 2019
Aims According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D).
Achiropita Pucci, Adriano Gatti, Agostino Consoli, Alessandra Dei Cas, Anna Solini, Annunziata Lapolla, Antonino Di Benedetto, Antonio Carlo Bossi, Arena, Salvatore, Avogaro Angelo, Berchialla, Paola, Bottigliengo, Daniele, Bruno Fattor, Buzzetti, Raffaella, Carla Giordano, Carlo Mannina, Carmela Vinci, D'Angelo, Paola, Edoardo Duratorre, Eleonora Devangelio, Emanuela Orsi, Enzo Bonora, Fabrizio Querci, Fadini, Gian Paolo, Federica D'Angelo, Francesco Andreozzi, Franco Cavalot, Franzetti, Ivano, Gaetano Leto, Gian Pio Sorice, Gianluca Aimaretti, Giorgio Sesti, Giovanni Grossi, Giuliana Cazzetta, Giuseppe Capobianco, Giuseppe Felace, Giuseppe Penno, Giuseppe Saglietti, Gloria Formoso, Ioannis Karamouzis, Ivana Zavaroni, Ivano Franzetti, Lucia Frittitta, Manfredi Rizzo, Massimiliano Petrelli, Massimo Boemi, Massimo Cigolini, Maurizio Poli, Natalino Simioni, Nino Cristiano Chilelli, Olga Lamacchia, Paola D'Angelo, Paola Silvia Morpurgo, Patrizia Li Volsi, Raffaella Buzzetti, Riccardo Bonadonna, Roberta Chianetta, Roberto Anichini, Salvatore Arena, Salvatore Piro, Sciannameo, Veronica, Silvestre Cervone, Susanna Morano, Vera Frison, Vinci, Carmela   +64 more
core   +1 more source

New era for useful add-on therapy (AOT) to diabetes by combined agents of insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) [PDF]

, 2020
Hiroshi Bando
openalex   +1 more source

Is There a Causal Link Between GLP‐1 Receptor Agonists and Non‐Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer, Joseph F. Rizzo III   +1 more
wiley   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

Diabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo, Nikolaj Vang Nielsen, Julie Drotner Mouritsen, Michael Einar Røder, Jakob Linnet   +4 more
wiley   +1 more source

Cardiometabolic Profiles of Oral and Subcutaneous Glucagon‐Like Peptide‐1 Receptor Mono‐Agonists in Adults With Overweight or Obesity: A Systematic Review and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To characterize the cardiometabolic profiles of oral and subcutaneous glucagon‐like peptide‐1 (GLP‐1) receptor mono‐agonists in adults with overweight or obesity, with or without type 2 diabetes (T2D), using network meta‐analysis (NMA).
Ying Lu, Jiajie Chen, Yuqing Guo, Hao Ding, Yu‐Lun Liu, Michelle A. Van Name, Mona Sharifi, Yuan Lu, Yong Chen   +8 more
wiley   +1 more source

Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Cardiovascular Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials

Journal of Diabetes
Background The cardioprotective effects of glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)‐based therapies in nondiabetic individuals with overweight or obesity remain underexplored.
Yue Yin, Minghan Zhang, Qiuyu Cao, Lin Lin, Jieli Lu, Yufang Bi, Yuhong Chen   +6 more
doaj   +1 more source

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.

, 2017
AIM: To investigate the mechanism of action for body weight loss with semaglutide. MATERIALS AND METHODS: This randomised, double-blind, placebo-controlled, two-period crossover trial investigated the effects of 12 weeks treatment with once-weekly ...
Axelsen, MB, Blundell, J, Finlayson, G, Flint, A, Gibbons, C, Hjerpsted, J, Kvist, T   +6 more
core   +1 more source

Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP‐1 Receptor Agonists: A Meta‐Analysis and Meta‐Regression of Randomised Controlled Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine whether on‐treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large‐scale trials of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs).
Masashi Hasebe, Hisashi Kamido, Chen‐Yang Su, Yamato Keidai, Daisuke Yabe, Satoshi Yoshiji   +5 more
wiley   +1 more source

Pharmacogenetics and target identification in diabetes [PDF]

, 2018
In diabetes, pharmacogenetics can be used both to identify patient subgroups who will have most benefit and/or least harm from a particularly treatment, and to gain insights into the molecular mechanisms of drug action and disease aetiology.
Ahlqvist, Babenko, Bain, Connelly, Dawed, Dujic, Dujic, Dujic, Emdin, Ewan R Pearson, Feng, Florez, Gloyn, Holstein, Holstein, Hsieh, Javorsky, Javorsky, Kang, Klen, Mahajan, Marso, Marso, Pearson, Pearson, Pearson, Pei, Ragia, Schroner, Scott, Shepherd, Srinivasan, Sundelin, The SIGMA Type 2 Diabetes Consortium, Van Leeuwen, Zhang, Zhou, Zhou, Zhou, Zhou   +39 more
core   +2 more sources